News

Investigators conducted a retrospective review that spanned 10 years with the goals of describing the clinical characteristics of choroidal metastasis in this patient population and report treatment outcomes after targeted therapy compared with conventional radiotherapy and/or chemotherapy.

The “Triangle sign” seen on ultrasound is a “distinctive and reliable” ultrasound feature for differentiating total choroidal detachments and suprachoroidal hemorrhages.

The investigators found that the premature births to be associated with vascular changes on ocular coherence tomography-angiography.

The NeurEYE research team will use millions of eye scans from Scottish optometrists to create the data set.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with retinitis pigmentosa.

DRSS stable/improved with OKT-TKI; drug well tolerated

Home-stored anti-VEGF drugs face risks from temperature changes, pointing to a need to protect efficacy and avoid dangerous contamination.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

They report a case of endophthalmitis and undertook a literature review to identify previous infections with this pathogen.

Cost among other factors may deter patients from screening, especially in rural and low-resource settings.

In the 5 patients with bilateral geographic atrophy (GA) who received a K8 implant in 1 eye, there was a mean reduction in GA lesion growth of 66% at 3 months.

The funding will support activities like formal pharmacology and toxicology testing.

The company's lead product candidate Duravyu (vorolanib intravitreal insert), f/k/a EYP-1901, is anticipating topline data from several clinical trials in 2026.

InflammX’s pipeline includes an orally dosed therapeutic candidate targeting intermediate age-related macular degeneration.

The new funding will allow the company to complete its ongoing Phase 2 trial of proprietary nanomedicine, migaldendranib, in patients with wet AMD and DME

The retrospective SING IMT study included 35 patients (55 years or older) with late-stage age-related macular degeneration (AMD).

Previously, Teva was established as the European commercialisation partner of FYB201, Formycon's biosimilar to ranibizumab (Lucentis).

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

OCU400 demonstrated meaningful improvement of 2-line gain (10 letters on ETDRS chart) in low-luminance visual acuity (LLVA) in treated eyes when compared to untreated fellow eyes.

City Therapeutics will develop a novel RNAi clinical candidate toward a specific disease target for intravitreal administration.

This phase 2b study (ASPIRE) is currently underway.

The application was refiled following a December 20, 2024, meeting between the US Food and Drug Administration (FDA) and Astellas.